Group 1 - The company has approved a share repurchase plan using its own funds and a special loan for stock repurchase, with a total amount between RMB 22 million and RMB 40 million, and a maximum price of RMB 18 per share, within a 12-month period [1] Group 2 - As of July 31, 2025, the company has repurchased a total of 1,067,387 shares, accounting for 0.2603% of the total share capital of 410 million shares, with a total expenditure of RMB 13,914,990.75 [2] Group 3 - The share repurchase is in compliance with relevant laws and regulations [3] Group 4 - The company will make repurchase decisions based on market conditions and will fulfill its information disclosure obligations in a timely manner [4]

Core Viewpoint - The company announced a share buyback program, indicating a commitment to returning value to shareholders and potentially signaling confidence in its future performance [2] Group 1 - As of July 31, 2025, the company has repurchased a total of 1,067,387 shares [2] - The repurchased shares represent 0.2603% of the company's total share capital of 410,000,000 shares [2]

格隆汇8月1日丨药康生物(688046.SH)公布，截至2025年7月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式累计回购公司股份1,067,387股，占公司总股本410,000,000股的比例为0.2603%，回购 成交的最高价为15.13元/股，最低价为10.52元/股，支付的资金总额为人民币13,914,990.75元（不含印花 税、交易佣金等交易费用）。 ...

证券代码：688046 证券简称：药康生物 公告编号：2025-054 上述回购股份符合法律法规的规定及公司回购股份方案。 江苏集萃药康生物科技股份有限公司 二、回购股份的进展情况 关于以集中竞价交易方式回购公司股份的进展公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司应在每个月的前 3 个交易日内公告截至上月 末的回购进展情况。现将公司回购股份进展的具体情况公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 截至 2025 年 7 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式累计回购公司股份 1,067,387 股，占公司总股本 410,000,000 股的比例为 0.2603%，回购成交的最高价为 15.13 元/股，最低价为 10.52 元/股，支付的资金总 额为人民币 13,914,990.75 元（不含印花税、交易佣金等交易费用）。 重要内容提示： | 回购方案首次披露日 | 2024/10/31 | | | | | | | | ...

Core Viewpoint - The company, Yaokang Biotechnology (688046.SH), has announced a share buyback program, indicating confidence in its stock value and future prospects [1] Summary by Relevant Categories Share Buyback Details - As of July 31, 2025, the company has repurchased a total of 1,067,387 shares through the Shanghai Stock Exchange, representing 0.2603% of its total share capital of 410,000,000 shares [1] - The highest price paid for the repurchased shares was 15.13 CNY per share, while the lowest price was 10.52 CNY per share [1] - The total amount spent on the share buyback was 13,914,990.75 CNY, excluding transaction fees such as stamp duty and commissions [1]

Group 1 - The CRO sector experienced a slight increase of 0.66% with a total capital inflow of 84.32 million [1] - A total of 27 stocks within the sector saw gains, while 11 stocks experienced declines [1] - The top declining stocks included Yaokang Bio (-3.64%), Zhaoyan New Drug (-2.68%), and Meidi West (-2.04%) [1] Group 2 - Notable stocks with significant capital inflow included Baicheng Pharmaceutical with a price of 48.06 and a rise of 6.05% [1] - Other stocks with positive performance included Heyuan Bio (+4.39%) and Jinkai Biotechnology (+2.76%) [1] - The stock with the highest capital outflow was Yao Stone Technology, which saw a decrease of 8.88% [1]

Core Viewpoint - The company is implementing a differentiated dividend distribution plan, which involves special handling of ex-rights and ex-dividend dates, in accordance with relevant laws and regulations [1][7]. Group 1: Reasons for Differentiated Dividend - The company approved a share repurchase plan using its own or self-raised funds, with a total repurchase amount between RMB 22 million and RMB 40 million, at a price not exceeding RMB 18 per share [2]. - The repurchased shares will be used for employee stock ownership plans or equity incentives, with a repurchase period of 12 months from the board's approval [2]. Group 2: Differentiated Dividend Plan - The company held its annual general meeting on May 28, 2025, and approved a profit distribution plan, proposing to distribute cash dividends of RMB 1.10 per 10 shares (including tax) [4]. - The total share capital of the company is 410 million shares, with 1,009,362 shares held in the repurchase account, leading to a base for cash dividend distribution of 408,990,638 shares [4]. Group 3: Calculation Basis for Differentiated Dividend - The company will only distribute cash dividends without capital reserve transfers or stock dividends, resulting in no change in circulating shares [4]. - The ex-rights and ex-dividend reference price calculations show minimal impact, with the absolute value of the impact being less than 1% [5].

Core Viewpoint - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. has announced a differentiated cash dividend distribution plan for the fiscal year 2024, with a proposed cash dividend of 0.11 yuan per share, approved at the annual shareholders' meeting on May 28, 2025 [1][2]. Summary by Relevant Sections Dividend Distribution Plan - The company plans to distribute a cash dividend of 1.10 yuan for every 10 shares held, which translates to 0.11 yuan per share [2][3]. - The total cash dividend amount is approximately 44,988,970.18 yuan, based on a total share count of 408,990,638 shares eligible for distribution after excluding shares held in the company's repurchase account [2][3]. Shareholder Rights and Exclusions - Shares held in the company's repurchase account will not participate in the dividend distribution, as per the regulations [1][5]. - The distribution will be based on the total share capital minus the shares in the repurchase account, which has been adjusted from 2,589,362 shares to 1,009,362 shares [2][3]. Tax Implications - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, while those holding for less than one year will have taxes deducted at the time of share transfer [5][7]. - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied to their dividends, resulting in a net dividend of 0.099 yuan per share [6][7]. Important Dates - The key dates for the dividend distribution include the record date, ex-dividend date, and the date of cash dividend payment, which are yet to be specified [4].

华泰联合证券有限责任公司 关于江苏集萃药康生物科技股份有限公司 差异化分红送转特殊除权除息处理事项的核查意见 核查意见 2023 年 12 月 25 日，公司召开第二届董事会第三次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有或自筹资 金通过集中竞价交易方式进行股份回购，回购股份将用于员工持股计划或股权激 励，回购股份的资金总额不低于人民币 2,000 万元（含），不超过人民币 4,000 万元（含），回购股份的价格不超过人民币 29 元/股（含），回购股份的期限自董 事会审议通过本次回购股份方案之日起 12 个月内。 2024 年 10 月 29 日，公司召开第二届董事会第八次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金和股 票回购专项贷款资金通过集中竞价交易方式进行股份回购，回购股份将用于员工 持股计划或股权激励，回购股份的资金总额不低于人民币 2,200 万元（含），不 超过人民币 4,000 万元（含），回购股份的价格不超过人民币 18 元/股（含），回 购股份的期限自董事会审议通过本次回购股份方案之日起 12 个月内。 ...

江苏集萃药康生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/10 | 2025/7/11 | 2025/7/11 | 一、 通过分配方案的股东大会届次和日期 证券代码：688046 证券简称：药康生物 公告编号：2025-053 本次利润分配方案经公司2025 年 5 月 28 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东 （公司回购专用证券账户除外）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的有关规定，上市公司回购专用账户中的股份，不享有股东大 会表决权、利润分配、公积金转增股本、认购新股和可转 ...